Bitcoin price today: dips to $92k as Fed cut doubts spark risk-off mood
MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH) announced Wednesday that its Board of Directors has approved a quarterly dividend of $0.08 per share for the quarter ended September 30, 2025. The dividend represents a modest 0.52% yield based on the current share price of $61.1, according to InvestingPro data.
The dividend will be payable on November 28, 2025, to shareholders of record as of November 17, 2025, according to a company press release.
Bio-Techne, a global life sciences company that provides tools and bioactive reagents for research and clinical diagnostics, generated over $1.2 billion in net sales during fiscal 2025 and employs approximately 3,100 people worldwide.
The company's Board of Directors will consider future cash dividends on a quarterly basis, the statement said.
Bio-Techne's products support scientific investigations into biological processes and disease progression while also aiding drug discovery efforts and providing means for clinical tests and diagnoses.
The announcement comes as part of the company's regular dividend program, which provides returns to shareholders while maintaining investment in its operations.
In other recent news, Bio-Techne Corporation reported its fourth-quarter earnings for fiscal year 2025, exceeding analysts' expectations. The company achieved an adjusted earnings per share of $0.53, surpassing the projected $0.50. Revenue for the quarter reached $317 million, slightly above the anticipated $315.54 million. In addition to these financial results, Bio-Techne announced the launch of its ProximityScope assay, a spatial biology solution designed to visualize protein interactions within tissue samples. This new technology works with Leica Biosystems' BOND RX staining platform, providing enhanced capabilities for researchers. Furthermore, Bio-Techne has made advancements in its spatial biology tools, enabling simultaneous RNA and protein detection on the same tissue section. These developments utilize the company's RNAscope ISH technology and Lunaphore COMET platform, which may benefit both translational research and clinical applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.